BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14600530)

  • 1. Acute tubular necrosis in a patient receiving tenofovir.
    Lee JC; Marosok RD
    AIDS; 2003 Nov; 17(17):2543-4. PubMed ID: 14600530
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir-related nephrotoxicity in HIV-infected patients.
    Barrios A; García-Benayas T; González-Lahoz J; Soriano V
    AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal lesions in HIV-1-positive patient treated with tenofovir.
    Créput C; Gonzalez-Canali G; Hill G; Piketty C; Kazatchkine M; Nochy D
    AIDS; 2003 Apr; 17(6):935-7. PubMed ID: 12660548
    [No Abstract]   [Full Text] [Related]  

  • 4. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
    Saumoy M; Vidal F; Peraire J; Sauleda S; Vea AM; Viladés C; Ribera E; Richart C
    AIDS; 2004 Aug; 18(12):1741-2. PubMed ID: 15280790
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
    Schaaf B; Aries SP; Kramme E; Steinhoff J; Dalhoff K
    Clin Infect Dis; 2003 Aug; 37(3):e41-3. PubMed ID: 12884188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir.
    Callens S; De Roo A; Colebunders R
    J Infect; 2003 Oct; 47(3):262-3. PubMed ID: 12963392
    [No Abstract]   [Full Text] [Related]  

  • 7. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
    Callens S; De Schacht C; Huyst V; Colebunders R
    J Infect; 2003 Aug; 47(2):188-9. PubMed ID: 12860159
    [No Abstract]   [Full Text] [Related]  

  • 8. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
    Herlitz LC; Mohan S; Stokes MB; Radhakrishnan J; D'Agati VD; Markowitz GS
    Kidney Int; 2010 Dec; 78(11):1171-7. PubMed ID: 20811330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603
    [No Abstract]   [Full Text] [Related]  

  • 10. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
    Shere-Wolfe KD; Verley JR
    Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
    [No Abstract]   [Full Text] [Related]  

  • 11. ASN clinical pathological conference. Tenofovir-related ATN (severe).
    Atta MG; Stokes MB
    Clin J Am Soc Nephrol; 2013 May; 8(5):882-90. PubMed ID: 23371959
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate.
    Kumar A
    Drugs; 2003; 63(15):1609-10. PubMed ID: 12887267
    [No Abstract]   [Full Text] [Related]  

  • 13. EU issues warning about HAART regimen.
    AIDS Patient Care STDS; 2004 Jan; 18(1):56-7. PubMed ID: 15080094
    [No Abstract]   [Full Text] [Related]  

  • 14. Warning issued on non-response rates.
    AIDS Patient Care STDS; 2003 Oct; 17(10):539. PubMed ID: 14588094
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate.
    Antoniou T
    Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens.
    Lafeuillade A; Jolly P; Chadapaud S; Hittinger G; Lambry V; Philip G
    J Acquir Immune Defic Syndr; 2003 Aug; 33(4):544-6. PubMed ID: 12869846
    [No Abstract]   [Full Text] [Related]  

  • 17. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution.
    Gaspar G; Monereo A; García-Reyne A; de Guzmán M
    AIDS; 2004 Jan; 18(2):351-2. PubMed ID: 15075563
    [No Abstract]   [Full Text] [Related]  

  • 18. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
    Perazella MA
    Kidney Int; 2010 Dec; 78(11):1060-3. PubMed ID: 21076445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does tenofovir increase efavirenz hepatotoxicity?
    Lattuada E; Lanzafame M; Carolo G; Gottardi M; Concia E; Vento S
    AIDS; 2008 May; 22(8):995. PubMed ID: 18453862
    [No Abstract]   [Full Text] [Related]  

  • 20. Renal safety of tenofovir in HIV treatment-experienced patients.
    Izzedine H; Isnard-Bagnis C; Hulot JS; Vittecoq D; Cheng A; Jais CK; Launay-Vacher V; Deray G
    AIDS; 2004 Apr; 18(7):1074-6. PubMed ID: 15096814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.